Starling Oncology, Inc.

STLN Healthcare Medical Care Facilities

Starling Oncology, Inc.’s revenue for fiscal 2025 (year ended December 2025) was $502.7 million, up 27.8% from fiscal 2024.

Revenue
+24.3%
EPS
+7.14%
Free cash flow
+167.1%
Total debt
−4.82%

Quarter to September 2026, against a year earlier

3.51 3.19 −47.61%
Market cap
$669.9M
P/E
0.0×
Fwd P/E
−40.3×
Dividend yield
—
F-score
4/9
Altman Z
1.42
Beneish M
−3.39
Dividend safety
n/a
Sep '26 From the 10-Q filed 6 Nov Jun '26 Mar '26 Dec '25 Older periods
Piotroski F-Score
— 5 4 4

+8 more TTM periods

ROE
143.21% 214.12% 775.91% 999.19%
ROA
(20.23%) (21.47%) (26.19%) (35.93%)
ROIC
0.00% (117.66%) (63.75%) (80.21%)
Return on Tangible Assets
(144.55%) (81.31%) (90.26%) (115.51%)
Average Days of Receivables
35.77 41.46 39.76 43.07
Free Cash Flow per Share
0.18 (0.03) (0.25) (0.30)
Free Cash Flow
18.83 (3.29) (25.73) (27.79)
Other line items

Show all line items

Columns are period end dates · fundamentals updated 6 Nov 2026